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Cutaneous malignant melanoma is a severe and sometimes life-threatening cancer. The molecular mechanism of melanomagenesis is
incompletely understood. Deregulation of apoptosis is probably one of the key factors contributing to the progression of melanoma.
The inhibitor of growth (ING) family proteins are candidate tumour suppressors which play important roles in apoptosis.
Downregulated expression of ING proteins have been reported in several tumour types, including the loss of nuclear expression of
p33ING1b in melanoma. As ING2 exhibits 58.9% homology with p33ING1b, we hypothesized that the aberrant expression of ING2
may be involved in melanomagenesis. Here, we used tissue microarray technology and immunohistochemistry to examine ING2
expression in human nevi and melanoma biopsies. Our data showed that nuclear ING2 expression was significantly reduced in radial
growth phase (RGP), vertical growth phase (VGP), and metastatic melanomas compared with dysplastic nevi (Po0.05). Our data
also revealed that nuclear ING2 expression was not associated with patient’s gender, age or tumour thickness, ulceration, American
Joint Committee on Cancer (AJCC) stage, tumour subtype, location and 5-year survival (P40.05). Taken together, our results
suggest that nuclear ING2 expression is significantly reduced in human melanomas and that reduced ING2 may be an important
molecular event in the initiation of melanoma development.
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Human cutaneous malignant melanoma originates from the
melanocytes of the skin or melanocytic lesions including common
acquired nevus, dysplastic nevus, congenital nevus and cellular
blue nevus. Once considered as an uncommon disease, the
incidence of malignant melanoma has doubled within the last 10
years in the US (Balch et al, 2001). It is estimated that an American
developing melanoma during his/her lifetime leaped from 1 in
1500 in 1960, to 1 in 68 in 2000, and is projected to increase to 1 in
50 by the year 2010 (Rigel, 2002; Dunlap et al, 2004). Primary
melanoma usually progresses from the nonmetastatic radial
growth phase to the vertical growth phase, in which the malignant
cells invade the dermis and develop the ability to metastasize
(Elder, 1999). The large majority of patients with early stages of
melanoma can be cured by surgical removal while 50% of patients
with distant metastasis die within the first 6 months after the
diagnosis (Balch et al, 2001; Schoenlaub et al, 2001). Melanoma is
highly resistant to conventional radio- or chemo-therapy. Dacar-
bazine (DTIC), the only FDA approved drug for treatment of
melanoma, yields a response rate of only 16% (Atallah and
Flaherty, 2005). Therefore, better understanding of the molecular
mechanism of melanoma progression and chemoresistance is
prompted for designing novel treatment regimes. P53, a central
sensor linking DNA damage to apoptosis, plays an essential role in
tumour suppression and chemosensitivity in many tumour types
(Li et al, 1998; Raffo et al, 2000; Fridman and Lowe, 2003).
However, mutational analysis reveals that the p53 gene is altered in
only approximately 11% of melanomas (Hussein, 2004). The low
mutation rate of p53 suggests that other tumour suppressor genes
may play important roles in pathogenesis of melanoma.
Recent studies suggest that ING family proteins function as
tumour suppressors. Five members of ING proteins have so far
been identified and they all share a conserved PHD domain in the
C-terminus (Campos et al, 2004). P33ING1b is the founding
member which has been shown to induce cell cycle arrest, to
enhance DNA repair and to promote apoptosis after DNA damage
events (Garkavtsev et al, 1998; Cheung et al, 2001; Cheung and Li,
2002). ING2 was cloned through a homology search with
p33ING1b and was found to be located to human chromosome 4
(Shimada et al, 1998). Besides, the common PHD zinc finger motif,
ING2 also contains a nuclear localisation signal (NLS) domain
and a unique leucine zipper domain that is thought to
mediate hydrophobic protein–protein interaction (Feng et al,
2002). ING2 is mainly localised in the nucleus with 74% in the
chromatin/nuclear matrix and 9% in the nucleoplasm in HT1080
fibrosarcoma cells (Gozani et al, 2003). Previous studies showed
that ING2 cooperated with p53 to induce G1-phase cell-cycle arrest
and enhance apoptosis in colorectal carcinoma RKO cells
(Nagashima et al, 2001). Pedeux et al (2005) recently reported
that ING2 regulates replicative senescence by cooperating with
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sp300 to mediate p53 acetylation. In addition, ING2 was able to
regulate nuclear response to DNA damage by interacting with
phosphoinositides (PtdInsPs) through the PHD domain (Gozani
et al, 2003).
We have recently demonstrated that ING2 plays an essential role
in cellular stress response to UV irradiation either by enhancing
nucleotide excision repair or promote UV-induced apoptosis in
melanoma cell lines (Chin et al, 2005; Wang et al, 2006). To further
investigate the role of ING2 in melanomagenesis, we used tissue
microarray (TMA) and immunohistochemistry to evaluate the
expression of ING2 in different stages of human melanocytic
lesions. Our results for the first time showed that nuclear ING2
expression was reduced in melanoma biopsies compared to
dysplastic nevi.
MATERIALS AND METHODS
TMA construction
Formalin-fixed, paraffin-embedded tissue blocks containing
normal nevi, dysplastic nevi, primary melanomas and metastatic
melanomas were used in this study. The diagnosis of melanocytic
lesions followed criteria from other groups (Keller and Maize,
1996; Metcalf, 1996). Sample collection was approved by the
University of British Columbia and was performed in accordance
with the Declaration of Helsinki Guidelines. All the tissue samples
were from 1990 to 1997 archives of the Department of Pathology,
Vancouver General Hospital. For each case, the most representa-
tive lesion area was selected and marked on haematoxylin–eosin-
stained slides. Taking into account the limitations of the
representative areas of the tumour, duplicate 0.6-mm-diameter
tissue cores were taken from each biopsy and the TMAs were
assembled using a tissue array instrument (Beecher Instruments,
Silver Spring, MD, USA). Multiple 4-mm sections were cut with a
Leica microtome and then transferred to adhesive-coated slides
using routine histology procedures. One section from each TMA
was routinely stained with haematoxylin and eosin. The remaining
sections were stored at room temperature for immunohisto-
chemistry staining.
Immunohistochemistry of TMA
The TMA slides were deparaffined by heating at 551C for
30min following by three washes with xylene, 5min each. Tissues
were then rehydrated in a series of 5-min washes in 100, 90 and
70% ethanol and rinsed with phosphate-buffered saline (PBS).
Antigen retrieval was performed by microwaving the samples for
4min at full power (800W) in 250ml of 10mM sodium citrate (pH
6.0). Endogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide for 20min and nonspecific binding was
blocked by universal blocking serum (DAKO Diagnostics,
Mississauga, Ontario, Canada) for 30min. The primary polyclonal
rabbit anti-ING2 antibody Ping2, a kind gift of Dr C Harris
(NIH, Bethesda, MD, USA), was diluted 1:250 and incubated at
41C overnight. After three washes, 2min each with PBS, the
sections were incubated with a biotinylated goat anti-rabbit
secondary antibody for 30min (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). After three washes with PBS for
2min each, horseradish peroxidase-streptavidin (Santa Cruz
Biotechnology) was added to the section for 30min, followed by
another three washes, 2min each with PBS. The samples were
developed with 3,3-diaminobenzidine substrate (Vector Labora-
tories, Burlington, Ontario, Canada) for 7min and counterstained
with haemotoxylin. Then the slides were dehydrated following a
standard procedure and sealed with coverslips. Negative controls
were performed by omitting ING2 antibody during the primary
antibody incubation.
Evaluation of immunostaining
ING2 staining intensity was evaluated blinded by three indepen-
dent observers (including one dermatopathologist) simulta-
neously, and a consensus score was reached for each core. In all,
11 normal nevi and 57 dysplastic nevi were evaluated for ING2
staining, and informative tumour staining and complete clinical
pathological information were obtained in 79 primary melanoma
cases and 43 metastatic melanoma cases. The staining intensity
was scored as negative (0), weak (1), moderate (2) and strong (3).
For ING2 staining intensity, 87% of the biopsies have uniform
staining between different cores. In the 13% cases with a
discrepancy between duplicated cores, the average score was
obtained. In addition, the percentage of cells showing staining in
the nucleus was assessed by counting a minimal 400 cells per tissue
core and the average percentage of duplicate biopsy cores was
calculated. The multiplication of the average intensity score and
the average percentage was used as the final staining score for
statistical analysis.
Statistical analysis
Nuclear ING2 expression among different melanocytic lesions as
well as its correlation with clinicopathological parameters of the
melanoma patients, including age, gender, tumour thickness,
location, histological subtype, tumour ulceration status and AJCC
staging was evaluated by Mann–Whitney test or Kruskal–Wallis
test. Survival curves were plotted according to Kaplan–Meier
method and the comparison of survival curves was performed with
the log-rank test. The Mann–Whitney and Kruskal–Wallis tests
were performed by using GraphPad Prism and the survival
analysis was performed with SPSS 11.5 (SPSS, Chicago, IL, USA).
A P-value o0.05 was considered significant.
RESULTS
Clinicopathological findings
The clinicopathological features of the melanomas for this study
are summarised in Table 1. In primary melanomas, 79 cases (50
male subjects and 29 female subjects) were available for the
evaluation of ING2 staining. The median age of the patients was 58
y ranging from age 25 to 92 years. There were 12 cases of RGP and
67 cases of VGP. For the thickness of these primary melanomas, 23
were p1.0mm, 27 were 1.01–2.0mm, 15 were 2.01–4.0mm and 14
were 44mm. For the tumour subtype, superficial spreading
melanoma accounted for 36 cases, lentigo maligna melanoma 13
cases, acrolentigous melanoma two cases, nodular melanoma 13
cases and the remaining 15 cases were unspecified. The majority of
the melanomas located in sun-protected sites (65 cases, trunk, arm,
leg and feet) while 14 located in sun-exposed sites (head and neck).
Tumour ulceration was found in 16 patients. Forty-three out of 50
metastatic melanoma cases were available for ING2 staining. There
are 29 male and 14 female, with age ranging from 27 to 89 (median
59 years). We also used AJCC criteria to evaluate ING2 expression
among 122 melanomas (79 primary melanomas and 43 metastatic
melanomas), 41 tumours were at stage I, 34 at stage II, 24 at stage
III and 23 at stage IV.
Clinically, dysplastic nevi can be identified as mild, moderate or
severe. While mildly and moderately dysplastic nevi can be closely
observed, severely dysplastic nevi should certainly be surgically
removed. In this study, information on 53 of 57 dysplastic nevi are
available for subcategorization: 22 mild, 20 moderate and 11
severe.
Reduced ING2 nuclear expression in human melanomas
We examined ING2 nuclear expression in normal nevi, dysplastic
nevi, primary melanomas and metastatic melanomas by immuno-
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shistochemistry (Figure 1). There is no significant difference in
ING2 nuclear expression between normal nevi and dysplastic nevi
(P40.05, Mann–Whitney test). No difference in ING2 expression
was found among mildly, moderately or severely dysplastic nevi
(P40.05, Kruskal–Wallis test). Reduced ING2 expression was
observed in RGP and VGP primary melanomas as well as
metastatic melanomas compared with dysplastic nevi (P¼0.029,
0.0001 and 0.0286, respectively, Mann–Whitney test). There are no
significant differences in ING2 nuclear expression among RGP,
VGP and metastatic melanomas (P40.05, Kruskal–Wallis test)
(Figure 2).
Correlation between ING2 nuclear expression and
clinicopathological parameters or 5-year patient survival
Tumour thickness, ulceration and AJCC stages are well-known
indicators for melanoma prognosis. However, no correlation was
found between ING2 nuclear staining and these parameters
(P40.05 for all) (Figure 3). In addition, no association was found
between ING2 nuclear expressions and other clinicopathological
parameters including age, gender, subtype and location of tumours
(data not shown). To investigate whether ING2 expression was
correlated with patient survival, Kaplan–Meier survival curves
were plotted to see if there was a relationship between ING2
nuclear expression and 5-year patient survival in primary
melanomas or metastatic melanomas. We defined the staining as
strong if the score is between 1.51 and 3.0 or weak if the score is
p1.5. Our results showed that ING2 nuclear expression did not
significantly correlate with both 5-year overall and disease-specific
patient survival in primary and metastatic melanomas (P40.05,
log-rank test) (Figure 4).
DISCUSSION
The main purpose of this study is to investigate if the novel
tumour suppressor ING2 is aberrantly expressed in human
cutaneous melanomas. Using the tissue microarray technology
and immunohistochemistry, we for the first time demonstrated
that ING2 nuclear expression is reduced in human melanomas
compared to dysplastic nevi (Figure 2). Although a number of
studies indicated that ING2 possesses tumour suppressive func-
tions, such as inducing growth arrest, senescence, apoptosis and
enhancing DNA repair (Nagashima et al, 2001; Gozani et al, 2003;
Chin et al, 2005; Pedeux et al, 2005; Wang et al, 2006), there is
limited information on ING2 expression level in human cancers.
There is only one recent report by Okano et al (2006) showing that
ING2 expression is reduced in six of seven lung cancer cell lines.
However, these authors did not detect any ING2 mutation in 31
human lung cancer cell lines and 30 lung cancer biopsies. Although
the reason for reduced ING2 expression in human melanomas is
unclear, we cannot rule out mutation of the ING2 gene in
melanoma because different tumour type may have different
mechanisms for gene inactivation. For example, reduced ING1
expression was found in 73% of non-small cell lung cancer
biopsies (Kameyama et al, 2003) and 44% of breast cancer
primaries (Toyama et al, 1999), while no missense mutation were
found in these lung cancer biopsies and only one missense
mutation was found in 377 breast cancer carcinomas (0.27%). On
the other hand, reduced nuclear ING1 expression was associated
with a much higher mutation rate (20%) of the ING1 gene in
human primary melanomas (Campos et al, 2004). In addition, loss
of heterozygosity of the region 4q32 in the long arm of
chromosome 4, which includes ING2 and SAP30, was found in
20% of basal cell carcinomas (Sironi et al, 2004), suggesting that
genetic alteration of the ING2 gene does occur in human tumours.
Future studies on ING2 expression and gene mutation in different
cancer types will provide further evidence on the important role of
this tumour suppressor in the pathogenesis of human cancers.
Similar levels of ING2 nuclear expression in melanomas
regardless of the growth phases (RGP vs VGP) (Figure 2), tumor
thickness, ulceration or AJCC staging (Figure 3) suggest that
reduced ING2 expression may be involved in the initiation, rather
than progression of melanoma. We have recently shown that ING2
plays an essential role for maintaining genomic stability upon UV
irradiation. ING2 acts as a DNA damage sensor for nucleotide
excision repair, as physiological level of ING2 is required for rapid
induction of histone H4 acetylation, chromatin relaxation and the
recruitment of repair recognition factor XPA to the photolesion
sites (Wang et al, 2006). ING2 can also enhance the removal of
DNA damage by triggering the apoptosis process when the DNA
damage is too severe. We have found that overexpression of ING2
significantly enhanced UV-induced apoptosis by downregulating
the expression of Bcl-2, promoting the translocation of the Bax
protein to the mitochondria, resulting in the mitochondrial
membrane potential change, release of cytochrome c and
Table 1 Clinicopathological parameters of 122 cases of melanomas
No. of Patients %
Primary melanoma
Age
p58 38 48
458 41 52
Gender
Male 50 63
Female 29 37
Tumour thickness (mm)
p12 3 2 9
1.01–2 27 34
2.01–4 15 20
441 4 1 7
Ulceration
Absent 63 80
Present 16 20
Tumour subtype
Superficial spreading melanoma 36 46
Lentigo maligna melanoma 13 16
Acrolentigous melanoma 2 3
Nodular melanoma 13 16
Unspecified 15 19
Tumour growth phase
Radial growth phase 12 15
Vertical growth phase 67 85
Site
a
Sun-protected 65 82
Sun-exposed 14 18
Metastatic melanoma
Age
p59 22 51
459 21 49
Gender
Male 29 67
Female 14 33
AJCC Stage
I4 1 3 4
II 34 28
III 24 20
IV 23 18
aSun-protected sites: trunk, arm, leg and feet. Sun-exposed sites: head and neck.
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sactivation of caspases-9 and -3 (Chin et al, 2005). As UV radiation
is the main environment factor for melanoma formation, reduced
ING2 expression would impair the removal of UV-damaged DNA,
leading to gene mutation and malignant cell transformation.
Our data that no significant correlation between ING2 expres-
sion and melanoma thickness or AJCC staging supports a multiple
genetic change model during melanoma pathogenesis. Many
different molecules in the apoptosis and survival pathways have
been shown to be involved in melanoma initiation and progres-
sion. It appears that defects in the apoptosis pathway mostly
attribute to the initiation step in melanoma pathogenesis,
while activated survival pathway often correlates with tumour
Figure 1 Representative images of ING2 immunohistochemical staining in human melanocytic lesions. Strong ING2 expression in adjacent normal
epidermis (A), normal nevi (B), dysplastic nevi (C), and weak ING2 staining in primary melanoma (D) and metastatic melanoma (E). Arrows indicate strong
staining in melanocyte. Magnification,  400.
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sprogression. For example, the expression of proapoptotic factor
Apaf-1, a p53 downstream effector, which links the release of
cytochrome c to the activation of caspase-9, is reduced in human
cutaneous melanomas compared with normal nevi (Dai et al,
2004). The expression of another p53 downstream effector PUMA
is significantly reduced in melanoma compared to dysplastic nevi
(Karst et al, 2005). Furthermore, the expression of proapototic
protein XAF1, which blocks the XIAP-mediated inhibition of
caspase-3 (Liston et al, 2001), is also reduced in human melanomas
(Ng et al, 2004). However, the expression of Apaf-1, PUMA and
XAF1 expression did not correlate with tumor thickness. On the
other hand, increased expression of integrin-linked kinase and
phospho-Akt in the PI3 kinase survival pathway has been observed
in melanoma and correlated with tumour thickness and 5-year
patient survival (Dai et al, 2003, 2005). Furthermore, reduced
expression of PTEN, the negative regulator of the PI3 kinase, was
also found to be reduced in melanoma and significantly associated
with tumour thickness (Goel et al, 2006). However, some factors
are involved in more than one step in melanoma pathogenesis. For
instance, although PUMA expression does not correlate with
tumour thickness in primary melanoma, it is further reduced in
metastatic melanoma and weaker PUMA expression is correlated
with a poorer 5-year patient survival (Karst et al, 2005). Based on
the complexity of the apoptotic and survival pathways which
govern the fate of a cell, additional studies on the timing of the
gene inactivation/overexpression in these pathways from the same
set of tumour biopsies and the interdependence among these
events will provide a more complete picture of the molecular
changes during melanoma pathogenesis.
Our data that reduced ING2 expression does not significantly
correlate with 5-year patient survival (Figure 4) is consistent with
the findings that ING2 reduction is an early event in the RGP and
does not correlate with tumour progression (Figures 2 and 3). On
the other hand, although it is not statistically significant, we
observed that patients with weaker ING2 expression have a trend
towards better prognosis for both overall and disease-specific 5-
year patient survival in primary melanomas (Figure 4). Interest-
ingly, decreased expression of p33ING1b was also associated with
better prognosis in childhood acute lymphoblastic leukemia
patients as well as in invasive bladder cancer (Nouman et al,
2002; Sanchez-Carbayo et al, 2003). Although the mechanism
underlying these phenomena is unclear, we propose that the
enhancement of DNA repair by ING2 (Wang et al, 2006) may
account for a better trend of 5-year patient survival in weaker
ING2 expression group because enhanced DNA repair have been
shown to reduce the cytotoxicity of anticancer drugs (Siddik,
2003). Future studies on the correlation between ING2 expression
and patient survival in a large set of melanoma biopsies from
patients with and without chemotherapy will provide a clearer
answer.
In summary, we found that ING2 nuclear expression is reduced
in human cutaneous melanomas compared to normal or dysplastic
nevi. These data, together with our previous findings that ING2
plays essential roles in cellular stress responses (Chin et al, 2005;
Wang et al, 2006), suggest the importance of this tumour
suppressor in the pathogenesis of melanoma.
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Figure 2 ING2 nuclear expression at different stages of melanocytic
lesions. There are less ING2 nuclear expression in RGP, VGP and
metastatic melanomas compared with dysplastic nevi (P¼0.029, 0.0001
and 0.0286, respectively, Mann–Whitney test).
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Figure 3 No correlation was found between ING2 nuclear expression
and tumour thickness (P40.05, Kruskal–Wallis test) (A) and tumour
ulceration (P40.05, Mann–Whitney test) (B) of primary melanomas, or
AJCC stages for all 122 melanoma cases (P40.05, Kruskal–Wallis test)
(C).
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Figure 4 ING2 nuclear expression and 5-year patient survival. ING2 nuclear expression is not correlated with 5-year overall (A, C) and disease-specific
survival (B, D) in primary melanoma patients (A, B) or metastatic melanoma patients (C, D).
ING2 expression in melanoma
FL uet al
85
British Journal of Cancer (2006) 95(1), 80–86 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
schromatin-associated protein ING2 functions as a nuclear phosphoinosi-
tide receptor. Cell 114: 99–111
Hussein MR (2004) The TP53 tumour suppressor gene and melanoma
tumourigenesis: is there a relationship? Tumour Biol 25: 200–207
Karst AM, Dai DL, Martinka M, Li G (2005) PUMA expression is
significantly reduced in human cutaneous melanomas. Oncogene 24:
1111–1116
Kameyama K, Huang CL, Liu D, Masuya D, Nakashima T, Sumitomo S,
Takami Y, Kinoshita M, Yokomise H (2003) Reduced ING1b gene
expression plays an important role in carcinogenesis of non-small cell
lung cancer patients. Clin Cancer Res 9: 4926–4934
Keller JM, Maize JC (1996) The clinical and histological differential
diagnosis of malignant melanoma. Semin Oncol 23: 693–702
Li G, Tang L, Zhou X, Tron V, Ho V (1998) Chemotherapy-induced
apoptosis in melanoma cells is p53 dependent. Melanoma Res 8: 17–23
Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig
CG, McBurney MW, Korneluk RG (2001) Identification of XAF1 as an
antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3: 128–133
Metcalf JS (1996) Melanoma: criteria for histological diagnosis and its
reporting. Semin Oncol 23: 688–692
Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang
XW, Yokota J, Riabowol K, Harris CC (2001) DNA damage-inducible
gene p33ING2 negatively regulates cell proliferation through acetylation
of p53. Proc Natl Acad Sci USA 98: 9671–9676
Ng KP, Campos EI, Martinka M, Li G (2004) XAF1 expression is
significantly reduced in human malignant melanoma. J Invest Dermatol
123: 1127–1134
Nouman GS, Anderson JJ, Wood KM, Lunec J, Hall AG, Reid MM, Angus B
(2002) Loss of nuclear expression of the p33(ING1b) inhibitor of growth
protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 55:
596–601
Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura
A, Shibuya M, Nagashima M, Harris CC, Kudoh S (2006) Alterations in
novel candidate tumor suppressor genes, ING1 and ING2 in human lung
cancer. Onco Rep 15: 545–549
Pedeux R, Sengupta S, Shen JC, Demidov ON, Saito S, Onogi H, Kumamoto
K, Wincovitch S, Garfield SH, McMenamin M, Nagashima M, Grossman
SR, Appella E, Harris CC (2005) ING2 regulates the onset of replicative
senescence by induction of p300-dependent p53 acetylation. Mol Cell
Biol 25: 6639–6648
Raffo AJ, Kim AL, Fine RL (2000) Formation of nuclear Bax/p53 complexes
is associated with chemotherapy induced apoptosis. Oncogene 19: 6216–
6228
Rigel DS (2002) The effect of sunscreen on melanoma risk. Dermatol Clin
20: 601–606
Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin
TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C (2003) Gene
discovery in bladder cancer progression using cDNA microarrays. Am J
Pathol 163: 505–516
Schoenlaub P, Sarraux A, Grosshans E, Heid E, Cribier B (2001) Survival
after cutaneous metastasis: a study of 200 cases. Ann Dermatol Venereol
128: 1310–1315
Shimada Y, Saito A, Suzuki M, Takahashi E, Horie M (1998) Cloning of a
novel gene (ING1L) homologous to ING1, a candidate tumour
suppressor. Cytogenet Cell Genet 83: 232–235
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene 22: 7265–7279
Sironi E, Cerri A, Tomasini D, Sirchia SM, Porta G, Rossella F,
Grati FR, Simoni G (2004) Loss of heterozygosity on chromosome
4q32-35 in sporadic basal cell carcinomas: evidence for the
involvement of p33ING2/ING1L and SAP30 genes. J Cutan Pathol 31:
318–322
Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A,
DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, Riabowol K (1999)
Suppression of ING1 expression in sporadic breast cancer. Oncogene 18:
5187–5193
Wang J, Chin MY, Li G (2006) The novel tumour suppressor
p33ING2 enhances nucleotide excision repair via inducement of
histone H4 acetylation and chromatin relaxation. Cancer Res 66:
1906–1911
ING2 expression in melanoma
FL uet al
86
British Journal of Cancer (2006) 95(1), 80–86 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s